Since 2015, a number of glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated improved CV outcomes regardless of glycemia control
All doses of orforglipron in the ATTAIN-2 trial demonstrated a dose-dependent reduction in body weight and HbA1c at 72 weeks, Nasreen Alfaris , MD, MPH, consultant at the Obesity, Endocrine and Metabolism Center at King Fahad Medical City in Riyadh, Saudi Arabia, said during a presentation
Theres no one-size-fits-all best GLP-1 drug for everyone
Be Prepared for Prior Authorization Even if covered, most plans require: Medical necessity documentation BMI thresholds Proof of previous weight-loss attempts 4
The medical team also emphasized the importance of regular follow-up appointments to monitor her progress, which would involve tracking her blood sugar levels, weight, and overall health